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Abstract 
Background: Hepatocellular carcinoma (HCC), a primary liver malignancy, is the most common cancer in males and 
fourth common cancer in females in Taiwan. HCC patients usually have a poor prognosis due to late diagnosis. It has 
been classified as a complex disease because of the heterogeneous phenotypic and genetic traits of the patients and 
a wide range of risk factors. Micro (mi)RNAs regulate oncogenes and tumor suppressor genes that are known to be 
dysregulated in HCC. Several studies have found an association between downregulation of miR‑122, a liver‑specific 
miRNA, and upregulation of paternally expressed gene 10 (PEG10) in HCC; however, the correlation between low miR‑
122 and high PEG10 levels still remains to be defined and require more investigations to evaluate their performance 
as an effective prognostic biomarker for HCC.
Methods: An in silico approach was used to isolate PEG10, a potential miR‑122 target implicated in HCC develop‑
ment. miR‑122S binding sites in the PEG10 promoter were evaluated with a reporter assay. The regulation of PEG10 
by miR‑122S overexpression was examined by quantitative RT‑PCR, western blotting, and immunohistochemistry in 
miR‑122 knockout mice and liver tissue from HCC patients. The relationship between PEG10 expression and clinico‑
pathologic features of HCC patients was also evaluated.
Results: miR‑122 downregulated the expression of PEG10 protein through binding to 3′‑untranslated region (UTR) of 
the PEG10 transcript. In miR‑122 knockout mice and HCC patients, the deficiency of miR‑122 was associated with HCC 
progression. The expression of PEG10 was increased in 57.3 % of HCC as compared to paired non‑cancerous tissue 
samples. However, significant upregulation was detected in 56.5 % of patients and was correlated with Okuda stage 
(P = 0.05) and histological grade (P = 0.001).
Conclusions: miR‑122 suppresses PEG10 expression via direct binding to the 3′‑UTR of the PEG10 transcript. There‑
fore, while PEG10 could not be an ideal diagnostic biomarker for HCC but its upregulation in HCC tissue still has 
predictive value for HCC prognosis.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer around the world and is the cause of nearly 
745,000 deaths worldwide each year [1]. Although a 
number of risk factors have been linked to HCC devel-
opment, including liver cirrhosis, hepatitis B and C viral 
infections, and excessive alcohol consumption [2]. HCC 
is frequently diagnosed at an advanced stage and poor 
prognosis. The complexity of the disease is due to pheno-
typic and genetic heterogeneity of affected patients and 
the multitude of risk factors. Treatment options for HCC 
are limited and patient resistance to standard chemo- and 
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resection and liver transplantation are the only treatment 
options. Identifying appropriate biomarkers is critical for 
early HCC detection and treatment initiation, which can 
improve survival rates.
Micro (mi)RNAs are expressed in a tissue-specific 
manner and play essential roles in the regulation of 
oncogenes and tumor suppressor genes in HCC [3, 4]. 
miR-122 is specifically expressed in the liver, where it 
accounts for 70  % of the total miRNA population [4, 5] 
and regulates lipid metabolism to maintain normal liver 
function [6, 7]. miR-122 expression was found to be 
downregulated in HCC tissue, suggesting that miR-122 
is associated with hepatocarcinogenesis and can serve as 
a biomarker for liver cancer [8–15]. miR-122 has many 
mRNA targets, including cyclin G1, Bcl2-like protein 2, 
CCAAT-displacement protein, and paternally expressed 
gene 10 (PEG10), all of which are overexpressed in HCC 
patients [12]. These results suggest that miR-122 has 
a tumor suppressor function in hepatocarcinogenesis. 
Indeed, mice with targeted deletion of the miR-122 gene 
exhibited a variety of phenotypes associated with human 
liver disease, providing a useful model for investigating 
the effects of miR-122 dysregulation in HCC patients [7].
Aberrant PEG10 expression has been linked to various 
human malignancies, including pancreatic, breast, and 
prostate cancers, B cell acute and chronic lymphocytic 
leukemia [16, 17], as well as HCC [18–21]. PEG10 is criti-
cal for parthenogenetic development in mice [22] and is 
known to stimulate cell proliferation via interaction with 
activin receptor-like kinase 1 which inhibits transforming 
growth factor β signaling [23] or with SIAH1, an inducer 
of apoptosis [20, 24]. Recent studies suggest a role for 
PEG10 in HCC progression [19, 25–27]; thus, overex-
pression of PEG10 is considered as a potential biomarker 
for HCC [28, 29], although the relationship between miR-
122 and PEG10 remains not well understood.
In this study, we identified PEG10 as a potential miR-
122 target by an in silico approach and suppresses it’s 
expression via miR-122 direct binding to the 3′-UTR of 
the PEG10 transcript. In order to clarify the regulatory 
interaction between miR-122 and PEG10, the expres-
sion levels of these two factors were examined in normal 
and tumor tissue from HCC patients. Our findings sug-
gest that overexpression of PEG10 can be used to predict 
HCC patient prognosis at early stages of the disease but 




Sense (pSM-miR-122S) and antisense (pSM-miR-122AS) 
miR-122 expression vectors were provided by Dr. Cliff 
Ji-Fan Lin [12]. The 3′-untranslated region (UTR) of 
PEG10 transcript was cloned into the NheI/XhoI sites 
downstream of the luciferase gene in the pmiR-GLO plas-
mid (Promega, Madison, WI, USA) to obtain pmiR-GLO-
PEG10-3′-UTR F1 to F5, PEG10 TS (targeted sequence), 
and PEG10 MTS (mutated targeted sequence). The oli-
gonucleotides contained the restricted linker for the 
NheI/XhoI-digested terminus and a 47-bp fragment cor-
responding to the 3′-UTR. The forward 47-bp fragments 
included a 29-bp upstream flanking sequence, 7- or 
8-bp miR-122 seed, and an 11-bp downstream flanking 
sequence in the 3′-UTR of putative miR-122 targeted 
genes (Fig. 3c). For mutation analysis, we substituted the 
6-nt core seed-matched site (CACTCC) with comple-
mentary bases (GTGAGG) (Fig.  3c). The miR-122 posi-
tive control targeting sequence, 5′-CTA GCA CAA ACA 
CCA TTG TCA CAC TCC AGA ATT CAC AAA CAC 
CAT TGT CAC ACT CCA C-3′, was also cloned into 
NheI/XhoI sites downstream of the luciferase gene in the 
pmiR-GLO plasmid to obtain pmiR-GLO-miR122 PTS 
(positive targeted sequence).
Cell culture and transfection
Cell culture and DNA transfection was carried out 
as previously described [30, 31]. HepG2, Hep3B, 
and 293T cells (HB-8065, HB-8064, and CRL-11268, 
respectively, from American Type Culture Collec-
tion, Manassas, VA, USA) were cultured in Dulbecco’s 
Modified Eagle’s Medium with 10 % fetal bovine serum 
and penicillin/streptomycin (Invitrogen, Carlsbad, CA, 
USA). The 293T cells were transfected using Maxifec-
tin reagent (Omics Biotechnology Co., Taipei, Taiwan). 
Enhanced green fluorescent protein expression from 
vectors pSM-miR-122S and pSM-miR-122AS was eval-
uated with an IX70 fluorescence microscope (Olympus, 
Tokyo, Japan).
miR‑122 knockout mice
miR-122a−/− mice were provided by Dr. Ann-Ping Tsou 
(National Yang Ming University). Chimeric mice were 
produced by crossing with wild-type C57BL/6 mice for 
germline transmission of the miR-122 allele. Homozy-
gous miR-122−/− mice were obtained by crossing het-
erozygous offspring [7].
Patient sample collection
Liver tissue from 147 surgically resected HCC specimens 
were collected between 1999 and 2015, which stored 
in the tissue bank of Keelung Chang Gung Memorial 
Hospital (Keelung, Taiwan). Twelve additional liver tis-
sue samples were obtained by surgical resection of HCC 
between July 2011 and May 2012 at Keelung Chang Gung 
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Memorial Hospital. HCC cases were selected based on 
the following criteria: patients over 20 years of age, with 
or without hepatitis virus infection, who received surgical 
resection. Exclusion criteria were as follows: the patient or 
his/her family did not agree to participate in the study; and 
patients with human immunodeficiency virus infection or 
other defined etiologies that could lead to liver fibrosis/
cirrhosis such as autoimmune hepatitis and alcoholic liver 
diseases. The research involving human participants in 
this study was approved by the Multicenter Research and 
Ethics Committee of Chang Gung Medical Foundation 
Institutional Review Board. The approval number is 100-
0364B. All patients were enrolled after signing and dating 
an approved informed consent. Patient clinical informa-
tion was collected according to the approved Institutional 
Review Board procedures (no: 100-0364B).
Quantitative real‑time PCR
Gene and miRNA expression levels were measured by 
qRT-PCR as previously described [32]. Total RNA was 
isolated from cells and tissues with TRIzol reagent (Inv-
itrogen), and 2 μg total RNA was reverse-transcribed into 
cDNA using SuperScript III (Invitrogen) according to the 
manufacturer’s instructions. The TaqMan assay (Applied 
Biosystems, Foster City, CA, USA) was used for qRT-PCR 
with the 7500 Real-Time PCR System (Applied Biosys-
tems) and default cycling conditions. Relative expression 
levels were determined from a standard curve generated 
from serial dilutions of cDNA samples and were normal-
ized to that of glyceraldehyde 3-phosphate dehydrogenase. 
Data are presented as histograms where each bar repre-
sents the mean ± SEM of data obtained from three inde-
pendent experiments.
Reporter assay
The protocol for the reporter assay has been previously 
described [30]. Briefly, 293T cells were co-transfected 
with miR-122 (pSM-miR-122S), antisense miR-122 
(pSM-miR-122AS), or target reporter plasmid. Lucif-
erase activity was measured with the Dual-Luciferase kit 
(Promega, Madison, WI) according to the manufacturer’s 
instructions, and relative protein levels are expressed as 
firefly/Renilla luciferase ratios.
Western blotting
Western blotting was carried out as previously described 
[30–34]. The 293T and HepG2 cells were transfected 
with the specified concentration of miR-122 (pSM-
miR-122S) or anti-sense miR-122 (pSM-miR-122AS), 
then cultured for 72 h, with PEG10 expression analyzed 
by western blotting. Total protein was extracted from 
patient samples and 293T and HepG2 cells using radio-
immunoprecipitation buffer with protease and phos-
phatase inhibitors (Roche Diagnostics, Indianapolis, IN, 
USA). Lysates were subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and proteins were 
electrotransferred to a membrane, which was probed 
with antibodies against PEG10 (4C10A7; Abnova, Tai-
pei, Taiwan) and β-actin (Sigma-Aldrich, St. Louis, MO, 
USA). Quantity One software (Bio-Rad, Hercules, CA, 
USA) was used to detect protein bands within the linear 
range of the scanner, and band intensity was quantified 
using AlphaImager 2200 software (Thermo Fisher Scien-
tific, Pittsburgh, PA). The ratio of PEG10 to β-actin was 
used as a quantitative measure of PEG10 regulation by 
miR-122.
Histological analysis of PEG10 expression in HCC patient 
samples
HCC and adjacent normal liver tissue samples were 
washed twice with phosphate-buffered saline (PBS), then 
immersed in 4  % paraformaldehyde for 2  h, followed 
by overnight immersion in 30  % sucrose. Samples were 
embedded in Optimal Cutting Temperature medium 
(Electron Microscopy Sciences, Hatfield, PA, USA), fro-
zen on dry ice, and stored at −80  °C. Sections were cut 
at a thickness of 6–8 μm and placed on glass microscope 
slides (Thermo Fisher Scientific, Waltham, MA, USA), 
which were stored at −20 °C. Sections were stained using 
the Vectastain Elite ABC kit (Vector Laboratories, Burl-
ingame, CA, USA) at room temperature, then permeabi-
lized with 0.5 % Triton X-100, blocked with 1 % bovine 
serum albumin in 1× PBS and 150 μl stock goat serum 
for 1  h, and washed with 0.1  M glycine washing buffer. 
Sections were incubated with polyclonal anti-PEG10 
antibody diluted 1:2000 in blocking buffer for 1  h, fol-
lowed by a 1 h incubation with a biotinylated secondary 
antibody. The sections were developed for 20  min in a 
peroxidase substrate solution (Vector Laboratories) and 
mounted with 50 % glycerol. Phase contrast images were 
obtained at 60× magnification with an inverted micro-
scope (Olympus).
Statistical analysis
Continuous variables are expressed as median with inter-
quartile range, while categorical variables are shown 
as frequencies and percentages. In univariate analysis, 
baseline characteristics were compared between PEG10 
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overexpression and control groups with the χ2, Fish-
er’s exact, or Wilcox rank-sum test as appropriate. All 
reported confidence intervals and tests were two-sided 
with a 5 % significance level. Data analysis was performed 
with R v.3.2.4 software (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
miR‑122 downregulates PEG10 protein expression
To investigate the relationship between miR-122 and 
PEG10, pre-miR-122 was overexpressed in 293T and 
HepG2 cells and determined the mRNA and protein 
expression levels of PEG10 by qRT-PCR and western 
blotting, respectively. The effect of miR-122 on PEG10 
mRNA levels was examined by quantifying the mRNA 
levels of PEG10 as well as miR-122S and miR-122AS 
in cells transiently transfected with pSM-miR-122S or 
pSM-miR-122AS constructs (Fig.  1). The mRNA level 
of PEG10 was unaltered upon miR-122 or miR-122AS 
overexpression in 293T cells (Fig.  1a). The protein level 
of PEG10 was only significantly decreased when miR-
122 overexpressed but not miR-122AS in both 293T and 
HepG2 cells (Fig. 1b, c).
We further to confirm miR-122 mediates the expres-
sion of PEG10 protein in vivo, the total RNA and whole 
cell lysate were extracted from liver tissue of the miR-122 
knockout mice and then quantified the relative expres-
sion of PEG10 mRNA and protein by qRT-PCR and west-
ern blotting, respectively. Figure 2a shows that there is no 
obvious correlation in mRNA expression level of PEG10 
between miR-122-deficient and wild-type mice. In con-
trast, the protein level of PEG10 was upregulated in miR-
122 knockout as compared to wild-type mice (Fig.  2c). 
These results indicate that miR-122 downregulated the 






















































































Fig. 1 PEG10 is regulated by miR‑122 at the post‑transcriptional level in 293T and HepG2 cells. a PEG10 mRNA levels were detected by qRT‑PCR 
and normalized to that of glyceraldehyde 3‑phosphate dehydrogenase (GAPDH) in 293T cells. b Western blot analysis of PEG10 expression in 293T and 
HepG2 cells transfected with miR‑122S and miR‑122AS. Tubulin was used as the loading control. c Overexpression of miR‑122 upon HepG2 cells 
transfection with miR‑122S and miR‑122AS, as determined by qRT‑PCR
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Direct interaction of miR‑122 with 3′‑UTR of PEG10
In silico analysis using TargetScan and microRNA.org 
resource (http://www.microrna.org/microrna/home.do). 
The analysis results indicate that there are nine putative 
miR-122 binding sites located in the 3′-UTR of PEG10 
transcript, i.e., 64, 102, 564, 934, 1310, 1735, 2310, 2403 
and 3420 (Fig.  3a). In this study, we performed a lucif-
erase reporter assay to determine whether PEG10 expres-
sion is directly mediated by miR-122. The full-length 
PEG10 3′-UTR and four deletion fragments were sub-
cloned into downstream of the luciferase gene in the 
pmiR-GLO reporter plasmid (Fig.  3a). Cotransfected 
293T cells with each plasmid, along with a miR-122S and 
measured the luciferase activity at 48 h post-transfection. 
The data suggest that the miR-122S target sites 2310 and 
2403 were found to be responsible for the decreased 
luciferase activity upon co-transfection with miR-122S 
(Fig. 3b).
To clarify the interaction between miR-122 and PEG10 
3′-UTR, sequences corresponding to miR-122 seed bind-
ing sites (Fig.  3c) were constructed [35]. Liver-specific 
transcription factors regulate miR-122, which in turn 
targets cut-like homeobox  1 during liver development 
[35]. The oligonucleotides containing the putative miR-
122 binding site(s) were designed and subcloned by 
ligating annealed oligonucleotides into the NheI/XhoI-
digested pmiR-GLO vector in the forward direction 
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Fig. 2 PEG10 is upregulated by miR‑122 deficiency in miR‑122 knockout (KO) mice. a PEG10 mRNA expression levels were determined by qRT‑PCR 
in the liver of wild‑type (WT) and miR‑122 KO mice and normalized to that of GAPDH. b miR‑122 expression in the liver of WT and miR‑122 KO, as 
determined by qRT‑PCR. c PEG10 protein level was increased in miR‑122 KO as compared to WT mice. Tubulin was used as the loading control




























PGK Firefly luciferase 3'UTR 558-311F
PGK Firefly luciferase 3'UTRF2 754-1869
PGK Firefly luciferase 3'UTRF3 2006-2872
PGK Firefly luciferase 3'UTRF4 3109-4120
PGK Firefly luciferase 3’UTRF5 13-5015
(bp)
3’-GUUUGU-GGUAACAGUGUGAGGU-5' hsa-miR-122
| : | | | | |   | | | | | | | | |
5’-UUAGCACCCAGAUUCACACUCCU-3' PEG10
2295 bp
PGK Firefly luciferase 3'UTR 2782-60023F
5’ CTAGC AGAGGAGAAATGATTTAGCACCCAGAT TCAGTGAGG TATGCCTGGAAG C
G TCTCCTCTTTACTAAATCGTGGGTCTA AGTCACTCC ATACGGACCTTC GAGCT 5’
5’ CTAGC AGAGGAGAAATGATTTAGCACCCAGAT TCACACTCC TATGCCTGGAAG C-3’
G TCTCCTCTTTACTAAATCGTGGGTCTA AGTGTGAGG ATACGGACCTTC GAGCT 5’PEG10 TS
miR-122 putative bind site
PEG10 MTS
5’ CTAGC ACAAACACCATTGTCACACTCCA GAATTC ACAAACACCATTGTCACACTCCA C
G TGTTTGTGGTAACAGTGTGAGGT CTTAAG TGTTTGTGGTAACAGTGTGAGGT GAGCT 5’
miR-122 PTS
PTS (Positive targeting sequence): miR 122 positive control targeting sequence (2x Targeting sites)
miR-122 PTS miR-122 PTSEcoRI
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pmiR-GLO-PEG10 MTS, and pmiR-GLO 122 PST were 
transiently transfected into 293T cells. At 48  h post-
transfection, the luciferase activity of pmiR-GLO-PEG10 
TS was reduced upon co-transfection with miR-122S but 
not miR-122AS (Fig. 3d). This decrease was abrogated by 
introducing a 6-bp mutation in the miR-122 binding site. 
These results indicate that miR-122 downregulates the 
PEG10 expression via direct binding to site 2310 in the 
3′-UTR of PEG10.
miR‑122 is downregulated while PEG10 is upregulated 
in HCC patients
miR-122 is downregulated in human HCC and has been 
considered as part of the miRNA signature for HCC. 
However, it is still not clear how miR-122 contributes 
to liver tumor progression. A qRT-PCR analysis of 12 
HCC tumors reveal that miR-122 expression levels were 
downregulated relative to adjacent non-cancerous tissue 
(Fig. 4a).
PEG10 was previously reported to be associated with 
increased cell proliferation in HCC patients [20]. In our 
study, we did not observe significant correlation between 
the downregulation of miR-122 and relative change of 
endogenous PEG10 protein levels in HCC (Fig. 4b); only 
8 of 12 (67  %) HCC patients had higher PEG10 protein 
expression in tumor as compared to normal adjacent 
tissue (Fig.  4b). Accordingly, there was no association 
between PEG10 mRNA levels in tumor and normal adja-
cent tissues that examined by qRT-PCR analysis (Fig. 4c). 
The analysis data revealing that in 9 of 12 (75  %) HCC 
patients, the PEG10 transcript was overexpressed in 
tumor tissue. These suggesting that factors other than 
miR-122 are also involved in regulation of PEG10 expres-
sion in HCC.
PEG10 protein expression is correlated with advanced 
histological grade and higher Okuda stage and alpha 
fetoprotein (AFP) level
We analyzed the clinical characteristics of 147 HCC 
patients from the Tissue Bank of Chang Gung Memorial 
Hospital in Keelung. Among patients with higher PEG10 
protein levels in tumor as compared to normal adja-
cent tissue, the mean patient age was 62.95 years (range 
26–85  years); 58 were male; 40 (48.2  %) were infected 
with the hepatitis B virus and 28 (33.7  %) with hepati-
tis C virus; 55 (66.3 %) had cirrhosis of the liver; and 12 
(14.5  %) exhibited tumor recurrence. Among patients 
in which PEG10 protein expression in tumor tissue was 
similar to or lower than in adjacent normal tissue, mean 
patient age was 62.31 years (range 37–84); 46 were male; 
31 (48.4  %) were infected with hepatitis B virus and 13 
(20.3  %) with hepatitis C virus; 42 (65.6  %) had cirrho-
sis of the liver; and 4 (6.3 %) exhibited tumor recurrence 
(Table 1).
PEG10 protein overexpression was detected in 83 of 
147 patients (56.5 %). A univariate analysis revealed that 
this was significantly associated with advanced histologi-
cal grade (P =  0.001), higher Okuda stage (P =  0.050), 
and elevated AFP level (P = 0.055).
Discussion
miRNAs regulate genes involved in cell proliferation 
and tissue homeostasis by modulating mRNA stabil-
ity and protein translation [36]. Accordingly, the dys-
regulation of miRNAs and their target genes is linked 
to tumor initiation and progression [37]. The results of 
our study demonstrated a negative regulatory relation-
ship between miR-122 and PEG10 in two different cell 
lines. These results are consistent with the study which 
(See figure on previous page.)
Fig. 3 miR‑122 directly binds to the 3′‑UTR of PEG10 transcript. a Schematic illustration of the luciferase reporter vector pmiR‑GLO‑PEG10‑3′‑UTR. 
Nine putative miR‑122 binding sites were identified by bioinformatic analysis (top) at positions 64, 102, 564, 934, 1310, 1735, 2310, 2403 and 3420. 
Four deletion fragments and the full‑length 3′‑UTR of PEG10 were cloned downstream of the luciferase gene at the NheI and XhoI sites. An expanded 
view of the seed region of miR‑122 in the PEG10‑3′‑UTR is shown. b Identification of the miR‑122 target region in the 3′‑UTR of PEG10 transcript. 
293T cells were co‑transfected with miR‑122S and the negative control (Vector) along with pmiR‑GLO‑PEG10‑3′‑UTR F1, pmiR‑GLO‑PEG10‑3′‑UTR F2, 
pmiR‑GLO‑PEG10‑3′‑UTR F3, pmiR‑GLO‑PEG10‑3′‑UTR F4, pmiR‑GLO‑PEG10‑3′‑UTR F5, or pmiR‑GLO‑miR122 PTS; luciferase activity was determined 
at 48 h post‑transfection. Renilla luciferase served as the internal control. Data represent the mean of three independent experiments, and error bars 
represent SD. c Schematic illustration of putative miR‑122 binding site in the 3′‑UTR of PEG10 transcript. For pmiR‑GLO‑PEG10 3′‑UTR MTS, seven 
nucleotides, ACACTCC, were replaced with AGTGAGG. MTS mutation. d Identification of the miR‑122 target sequence in the 3′‑UTR of PEG10 tran‑
script. 293T cells were co‑transfected with either miR‑122S or empty vector along with pmiR‑GLO‑PEG10‑3′‑UTR TS, pmiR‑GLO‑PEG10‑3′‑UTR MTS, or 
pmiR‑GLO‑miR122 PTS constructs
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transient transfected pre-miR122 into HepG2 cells 
caused a decrease in PEG10 protein level without altering 
the mRNA level [38]. We also showed with a luciferase 
reporter assay that miR-122 directly bound to the 3′-UTR 
of the PEG10 transcript (2006–2872 bp) and further sup-
press the translation of PEG10.
Previous studies shown that PEG10 highly expressed in 
hepatoma cell lines and miR-122 downregulated in HCC 
tissue [4, 7, 39, 40]. These findings imply that expression 
of miR-122 and PEG10 is inversely related in HCC. We 
found that miR-122 was expressed at low levels in nor-
mal tissue adjacent to tumors in all patient samples, while 
PEG10 levels varied between specimens. In some cases, 
PEG10 mRNA was downregulated whereas the protein 
expression was upregulated relative to normal adjacent 
tissue, which is consistent with miR-122-mediated trans-
lational repression of PEG10; however, there was still no 
correlation between PEG10 and miR-122 levels in HCC 
patients. In China and Hong Kong, 39.5 and 80 % of HCC 
patients, respectively, have increased copy numbers of 
the PEG10 gene [26], while PEG10 mRNA is detected in 
67, 80 and 67 % of HCC cases in China, Hong Kong, and 
Taiwan, respectively [19, 26]. In Korea, overexpression of 
PEG10 protein was detected in 67.9 % of HCC cases, and 
was correlated with younger age, female, higher Edmond-
son grade, microvascular invasion, intrahepatic metasta-
sis, higher American Joint Committee on Cancer T stage, 
and elevated AFP level [25]. By comparison, we observed 
overexpression of PEG10 protein has been found in 
57.3  % of HCC cases in Taiwan. Advanced histologi-
cal grade, higher Okuda stage, and high AFP level were 
risk factors for poor survival. The discrepancies between 
these reported values may be attributed to the existence 
of more than one mechanism regulating PEG10 expres-
sion in HCC.
Our findings demonstrate that miR-122 normally 
downregulates PEG10 protein expression and this regula-
tion is lost in HCC (Fig. 5), suggesting that the combina-
tion of downregulation of miR-122 and upregulation of 
PEG10 protein can be serve as early biomarkers for iden-
tifying an HCC subpopulation that is at high risk for poor 
outcome.
Conclusions
miR-122 suppressed PEG10 expression at translation level 
but not the mRNA level in cell lines and mouse model via 
direct binding to the 3′-UTR of PEG10 transcript. Sig-
nificantly, PEG10 protein expression level was positively 
(See figure on previous page.)
Fig. 4 miR‑122 and PEG10 expression levels in HCC tissue. a miR‑122 expression levels in HCC. Total RNA was extracted from 12 paired cancerous 
and adjacent normal tissues from HCC patients and miR‑122 level was quantified by qRT‑PCR. b Comparison of PEG10 expression in 12 paired can‑
cerous and adjacent normal tissues from HCC patients by western blotting. Data represent the mean of three independent experiments and were 
normalized to the level of β‑actin, and are presented as relative intensity (right panel). c PEG10 mRNA expression level in cancerous and adjacent 
normal tissue from HCC patients, as determined by qRT‑PCR
Table 1 Association between  PEG10 expression and  clini-
cal characteristics in  147 hepatocellular carcinoma 
patients
AJCC American Joint Committee on Cancer, BCLC Barcelona Clinic Liver Cancer, 
HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein
PEG10 (+) PEG10 (−) P value
N = 83 N = 64
Age (mean) 62.95 62.31 0.662
Gender (M) 58 (69.9 %) 46 (71.9 %) 0.792
Tumor size (cm) 0.231
 <2 17 (20.5 %) 7 (10.9 %)
 2–5 39 (47.0 %) 30 (46.9 %)
 >5 27 (32.5 %) 27 (42.2 %)
Vascular invasion 32 (38.6 %) 25 (39.1 %) 0.950
Liver cirrhosis 55 (66.3 %) 42 (65.6 %) 0.935
AJCC T‑stage 0.144
 I 49 (59.0 %) 36 (56.3 %)
 II 17 (20.5 %) 11 (17.2 %)
 III 16 (19.3 %) 11 (17.2 %)
 IV 1 (1.2 %) 6 (9.4 %)
BCLC stage 0.159
 0 9 (10.8 %) 2 (3.1 %)
 A 44 (53.0 %) 34 (53.1 %)
 B 26 (31.3 %) 27 (42.2 %)
 C 4 (4.8 %) 1 (1.6 %)
Okuda stage 0.050
 I 79 (95.2 %) 55 (85.9 %)
 II 4 (4.8 %) 9 (14.1 %)
Etiology 0.173
 Non‑viral 11(13.3 %) 15 (23.8 %)
 HBV 40 (48.2 %) 31 (48.4 %)
 HCV 28 (33.7 %) 13 (20.3 %)
 Both 4 (4.8 %) 5 (7.8 %)
Histological grade 0.001
 Well 6 (7.2 %) 19 (29.7 %)
 Moderate 61 (73.5 %) 32 (50 %)
 Poor 16 (19.3 %) 13 (20.3 %)
Recurrence (>2 year) 12 (14.5 %) 4 (6.3 %) 0.113
AFP (>500 ng/ml) 17 (30.1 %) 5 (15.6 %) 0.055
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correlated with advanced histological grade and Okuda 
stage and high AFP level. Further studies are needed in 
order to determine whether other factors besides miR-122 
regulate PEG10 expression in HCC.
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